Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/4/2009

EAST BRUNSWICK, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three and nine months ended September 30, 2009, ending the quarter with $67.5 million in cash and short-term investments, a reduction of $11.1 million from December 31, 2008. In October 2009, we raised $60.9 million in cash, net of $4.8 million of offering costs from an underwritten public offering of 4,945,000 shares of our common stock. The effect of combining the offering with our existing cash brings Savient to approximately $128.4 million in cash and short-term investments as of September 30, 2009, on a pro forma basis.

"Our strengthened cash position will support future important initiatives in addition to our focused efforts for the resubmission of our Biologics License Application for KRYSTEXXA(TM) to the U.S. Food and Drug Administration for the treatment of chronic gout in patients refractory to conventional treatment, which we expect will be submitted in early 2010," stated Paul Hamelin, President of Savient.

Operational Key Events:

  • During July 2009, we completed the dosing phase of our open label extension (OLE) study for KRYSTEXXA. This study is currently in an observation only stage.
  • In July 2009, we received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) stating that the FDA at that time could not approve our Biologics License Application (BLA) for KRYSTEXXA. The complete response letter cited deficiencies with the chemistry, manufacturing and controls (CMC) section of the BLA and also provided a draft of the proposed labeling and further guidance regarding a Risk Evaluation and Mitigation Strategy (REMS).
  • Our requested Type A meeting with the FDA occurred on
    '/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... HOUSTON, Aug. 24, 2011 eCardio Diagnostics ( www.ecardio.com ... annual Inc. 500|5000, an exclusive ranking of the nation,s ... consecutive year, ranking #912 overall and #65 in the ... of 335%. The list represents the most ...
... Corporation (NYSE: CVS ) today announced that ... repurchase program for up to $4.0 billion of the ... is effective immediately, permits the company to effect the ... open market repurchases, privately negotiated transactions, accelerated share repurchase ...
Cached Medicine Technology:Inc. Magazine Unveils Its Annual Exclusive List of America's Fastest-Growing Private Companies—the Inc. 500|5000 2CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $4 Billion of Common Stock 2CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $4 Billion of Common Stock 3
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... April 2014) Population Council scientists and their partners have ... and can prevent the transmission of multiple sexually transmitted ... animals: HIV, herpes simplex virus 2 (HSV-2), and human ... data that the gel is effective against multiple strains ... the vagina against all three viruses of at least ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... , , WASHINGTON, Aug. 27 The Office ... a free speech lawsuit filed by a prominent physician group, and ... The White House has "unlawfully collected information on political speech ... chill opposition to its plans for health care reform, according to ...
... , Leaders must take responsibility for patient ... 27 A new Joint Commission Sentinel Event Alert ... prevent errors by taking the zero-defect approach used in other high-risk ... advocating greater involvement of health care trustees, executives, and physician leaders, ...
... , , , Lifetime of Achievement Traces Arc ... on October 12 on Fifth Ave. in New York ... YORK, Aug. 27 Kenneth G. Langone, investment banker, venture capitalist and philanthropist, will be ... , , Mr. Langone, a co-founder of Home Depot and chairman of ...
... Case Managers Must Become Key Element of Any ... Ark., Aug. 27 The Case Management Society of America (CMSA) announced ... Case management is a collaborative process of assessing, planning, facilitating, and coordinating ... , Margaret (Peggy) Leonard, MS, RN-BC, FNP, CMSA,s President notes ...
... victory for families who dug into their own pockets to ... a $3.5-million grant to the Boston-based Tay-Sachs Gene Therapy Consortium ... in a bid to halt the fatal genetic disorder. ... the NIH award was eagerly awaited by Tay-Sachs families and ...
... ... its recent launch of accounts on the popular social networking sites, Facebook, Twitter, and ... Las ... medical consultations, diagnoses, prescriptions, and doctors, excuses for work and school, expands its outreach ...
Cached Medicine News:Health News:White House Sued Over Free Speech Violations In Healthcare Battle: Doctor & Patient Groups Say White House Intended to Shut Up Opponents 2Health News:Joint Commission Alert: Effective Leadership Critical to Preventing Medical Errors 2Health News:Joint Commission Alert: Effective Leadership Critical to Preventing Medical Errors 3Health News:Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal 2Health News:Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal 3Health News:Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal 4Health News:CMSA Announces New Model ACT Supporting Case Management Programs 2Health News:CMSA Announces New Model ACT Supporting Case Management Programs 3Health News:NIH grant advances Tay-Sachs disease gene therapy 2Health News:NIH grant advances Tay-Sachs disease gene therapy 3Health News:KoolDocs.com Increases Online Presence through Social Networking Premium Online Medical Consultation Service Now on Facebook, Twitter, and LinkedIn 2
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
NephroMax High Pressure Nephrostomy Balloon Catheter (Kit) allows one-step, atraumatic dilatation of the nephrostomy tract....
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
... used to dilate the musculofacscial tract and ... a percutaneous procedure. The Ultraxx balloon has ... to the catheter shaft at the tip. ... the dilating tract to the surgical site, ...
Medicine Products: